Apnimed (APMD) Stock Overview

Operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. More details

APMD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	3/6
Financial Health	1/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (15.6x) is below the US market (19.3x)

Became profitable this year

Risk Analysis

Debt is not well covered by operating cash flow

Shares are highly illiquid

Negative shareholders equity

APMD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW476,058 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

476,058 investors already sharing narratives

View all narratives

Apnimed, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Apnimed
Historical stock prices
Current Share Price	US$16.00
52 Week High	US$0
52 Week Low	US$0
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	APMD	US Pharmaceuticals	US Market
7D	n/a	-0.9%	0.5%
1Y	n/a	50.6%	16.5%

Return vs Industry: Insufficient data to determine how APMD performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how APMD performed against the US Market.

Price Volatility

Is APMD's price volatile compared to industry and market?
APMD volatility
APMD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.2%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.2%

Stable Share Price: APMD's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine APMD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	65	Kevin Lind	apnimed.com

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Apnimed, Inc. Fundamentals Summary

How do Apnimed's earnings and revenue compare to its market cap?
APMD fundamental statistics
Market cap	US$569.99m
Earnings (TTM)	US$39.00m
Revenue (TTM)	US$120.15m

15.6x

P/E Ratio

5.1x

P/S Ratio

Is APMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APMD income statement (TTM)
Revenue	US$120.15m
Cost of Revenue	US$7.54m
Gross Profit	US$112.61m
Other Expenses	US$73.61m
Earnings	US$39.00m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	1.03
Gross Margin	93.73%
Net Profit Margin	32.46%
Debt/Equity Ratio	-66.2%

How did APMD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/31 10:19
End of Day Share Price	2026/07/30 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apnimed, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Apnimed, Inc.NasdaqGM:APMD Stock Report